Basket | Login


Alector announces the recruitment of the first participant in Phase Ib trial of AL002 for AD

Monday 06 May 2019

On 6 May, Alector, a biotechnology company developing immuno-neurology therapies to treat neurodegenerative diseases, announced the dosing of the first participant with Alzheimer’s disease (AD) in its Phase Ib trial of AL002, a monoclonal antibody that enhances the activity of TREM2. The Phase Ib trial named INVOKE is a multi-centre, randomised, double-blind and placebo-controlled study evaluating the safety, tolerability and pharmacokinetics of multiple doses of AL002 in people with mild to moderate AD and healthy adults.  It will measure target specific biomarkers in both plasma and cerebrospinal fluid.